MedEsthetics magazines offers business education and in-depth coverage of the latest noninvasive cosmetic procedures for physicians and practice managers working in the medical aesthetics industry.
Issue link: https://medesthetics.epubxp.com/i/156138
NEWS & EVENTS PHASE III RESULTS OF TOPICAL BRIMONIDINE FOR ROSACEA RELEASED Topical brimonidine tartrate gel 0.5% (Galderma, galderma.com) is significantly more efficacious than vehicle in the treatment of rosacea-related erythema. Joseph Fowler, MD, et al, have published the findings of two phase III pivotal trials on brimonidine in the Journal of Drugs in Dermatology (June 2013). The multicenter, randomized, double-blind, parallel-group studies included 260 subjects and 293 subjects, respectively, and were carried out between May 2011 and November 2011. In both studies half of the patients used topical vasoconstrictor brimonodine tartrate gel 0.5% once daily for four weeks, the other half of patients used vehicle only. The subjects were evaluated on days 1, 15 and 29 of the treatment period and again at four weeks post-treatment. The majority of subjects were female, Fitzpatrick skin type II. The endpoint profile of success was defined as a two-grade improvement in Clinician's Erythema Assessment (CEA) and Patient's Self-Assessment (PSA). The researchers reported that "Topical brimonidine tartrate gel 0.5% was significantly more efficacious than vehicle throughout 12 hours on days 1, 15 and 29, with significant difference observed as early as 30 minutes after the first application on day 1." There was no clinically meaningful rebound of erythema seen during the followup phase. Adverse events were greater among the treated groups, but events were reported as dermatological, mild and transient in nature. The FDA is slated to complete its review of brimonidine during the second half of 2013. QUINNOVA TO CO-PROMOTE REFISSA Suneva Medical, a privately held aesthetics Whatever you need, we've got you covered With our 3 creamy mineral foundations each with soothing zinc oxide, SPF 20, superior coverage and a natural looking fnish 1-916-939-9888 1-800-476-0226 toll free w w w. i l l u m i n a re c o s m e t i c s . c o m 70 SEPTEMBER/OCTOBER 2013 | MedEsthetics company, has selected Quinnova Pharmaceuticals, a provider of therapeutic skin and wound products in the United States, to co-promote ReFissa. ReFissa is the only FDA approved 0.05% tretinoin emollient cream indicated for the treatment of fine wrinkles, mottled hyperpigmentation, and tactile roughness of facial skin. "Quinnova has structured its unique delivery platforms to provide superior products that address a variety of skin conditions," said Jeffrey Day, Quinnova's president, CEO and founder. "As one of the most effective treatments for fine facial wrinkles, ReFissa strengthens our product portfolio, adding a coveted topical aesthetic solution to our portfolio and enhancing our value among healthcare professionals." CRUTCHFIELD HONORED AMONG MOST INFLUENTIAL LEADERS OF 2013 Dermatologist Charles E. Crutchfield III, MD, of Crutchfield Dermatology has been selected by TheGrio.com for inclusion on its 2013 list of most influential African-American history and industry leaders. Former honorees include Michelle Obama, Beyonce, Adrian Peterson, Tyler Perry, Neil deGrasse Tyson (physicist and astronomer), Susan Rice, Gabby Douglas, Maya Rudolph, Keith Ellison, Tyra Banks, Rihanna, Ken Williams (general manager, Chicago White Sox), Wynton Marsalis, Charles Bolden, LeBron James and Oprah Winfrey. "I am privileged to have been selected among such an exceptional group of people for this prestigious nomination," said Dr. Crutchfield. "I am truly appreciative and humbled for the recognition of receiving this outstanding honor." TheGrio.com, a division of NBC News, recognized Dr. Crutchfield for his commitment to his specialty, practice, patients and his community, which he supports through a variety of philanthropic efforts. Dr. Crutchfield is a board certified dermatologist and Fellow of the American Academy of Dermatology. He is also a clinical professor of dermatology at the